1-2 of 2
Christine Falge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Nadine Pletsch, Susanne Saussele, Michael Lauseker, Armin Leitner, Susanne Jung-Munkwitz, Samina Shazi, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Thomas Schenk, Susanne Schnittger, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Leopold Balleisen, Hermann Einsele, Anthony D. Ho, Christine Falge, Mathias Hänel, Michael Pfreundschuh, Lothar Kanz, Frank Stegelmann, Claus-Henning Köhne, Stephan Kremers, Karsten Spiekermann, Wolfgang E Berdel, Cornelius F. Waller, Martin Bentz, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 862.
https://doi.org/10.1182/blood.V114.22.862.862
Published: 2009
Journal Articles

Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.

Eckhart Weidmann, MD, PhD, Georg Hess, MD, Stefan W. Krause, MD, PhD, Holger Hebart, MD, PhD, Martin Dreyling, MD, PhD, Marion Subklewe, MD, Christine Falge, MD, Kai U. Chow, MD, PhD, Elke Jaeger, MD, PhD, Parisis S. Mitrou, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 2640.
https://doi.org/10.1182/blood.V104.11.2640.2640
Published: 2004